Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions - Archive ouverte HAL Access content directly
Journal Articles OncoImmunology Year : 2020

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

Lorena Incorvaia
  • Function : Author
Daniele Fanale
  • Function : Author
Giuseppe Badalamenti
  • Function : Author
Camillo Porta
  • Function : Author
Daniel Olive
Centre de Recherche en Cancérologie de Marseille
Ida de Luca
  • Function : Author
Chiara Brando
  • Function : Author
Mimma Rizzo
  • Function : Author
Carlo Messina
  • Function : Author
Mattia Rediti
  • Function : Author
Antonio Russo
  • Function : Author
Viviana Bazan
  • Function : Author
Juan Lucio Iovanna
  • Function : Author
Centre de Recherche en Cancérologie de Marseille

Domains

Life Sciences [q-bio] Immunology

Jacques Nunès  : Connect in order to contact the contributor

https://hal-amu.archives-ouvertes.fr/hal-03152735

Submitted on : Thursday, February 25, 2021-6:26:39 PM

Last modification on : Friday, March 24, 2023-2:53:21 PM

Consult the full text

Dates and versions

hal-03152735 , version 1 (25-02-2021)

Identifiers

Cite

Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Camillo Porta, Daniel Olive, et al.. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. OncoImmunology, 2020, 9 (1), pp.1832348. ⟨10.1080/2162402X.2020.1832348⟩. ⟨hal-03152735⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

CNRS UNIV-AMU CRCM
11 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More